[Translation] A randomized, open-label, two-dose, single-dose, two-period crossover design phase I clinical study to evaluate the PK of LN006 dry suspension from Shanghai Huiyong Pharmaceutical Co., Ltd. and berberine hydrochloride tablets from Shanghai Xinyi Tianping Pharmaceutical Co., Ltd. in healthy subjects under fasting state
主要目的:
比较健康成年受试者单次口服上海惠永制药有限公司的 LN006 干混悬剂和上海信谊天平药业有限公司的盐酸小檗碱后系统及肠道暴露的差异;
次要目的:
评价健康成年受试者单次口服上海惠永制药有限公司的 LN006 干混悬剂和上海信谊天平药业有限公司的盐酸小檗碱片后的安全性。
[Translation] Primary purpose:
To compare the differences in systemic and intestinal exposure after a single oral administration of LN006 dry suspension of Shanghai Huiyong Pharmaceutical Co., Ltd. and berberine hydrochloride tablets of Shanghai Xinyi Tianping Pharmaceutical Co., Ltd. in healthy adult subjects;
Secondary purpose:
To evaluate the safety of LN006 dry suspension of Shanghai Huiyong Pharmaceutical Co., Ltd. and berberine hydrochloride tablets of Shanghai Xinyi Tianping Pharmaceutical Co., Ltd. in healthy adult subjects after a single oral administration.